On May 19, 2016 CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) reported that data highlighting pacritinib, including additional safety and long-term follow up data from the Phase 3 PERSIST-1 clinical trial, will be presented at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting to be held June 3-7 in Chicago, IL (Press release, CTI BioPharma, MAY 18, 2016, View Source;p=RssLanding&cat=news&id=2169602 [SID:1234512572]). The abstracts are available on the ASCO (Free ASCO Whitepaper) website at www.asco.org. Details regarding the poster presentations, which will include additional data not available in the abstracts, follow.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia
First Author: Claire Harrison, M.D., Guy’s and St. Thomas’ NHS Foundation Trust, Guy’s Hospital, London, United Kingdom
Date/Time: Monday, June 6 at 8:00 a.m.-11:30 a.m. CT
Poster Discussion Session: Monday, June 6, 11:30 a.m.-12:45 p.m. CT in Room E354b
Location: Hall A
Poster Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #7011 / Poster Board #3

Pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial
First Author: Ruben Mesa, M.D., Mayo Clinic Cancer Center, Chair of the Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ
Date/Time: Monday, June 6 at 8:00 a.m.-11:30 a.m. CT
Location: Hall A
Poster Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #7065 / Poster Board #57

Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy
First Author: Claire Harrison, M.D., Guy’s and St. Thomas’ NHS Foundation Trust, Guy’s Hospital, London, United Kingdom
Date/Time: Monday, June 6 at 8:00 a.m.-11:30 a.m. CT
Location: Hall A
Poster Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #7066 / Poster Board #58

Pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial
First Author: Ruben Mesa, M.D., Mayo Clinic Cancer Center, Chair of the Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ
Date/Time: Monday, June 6 at 8:00 a.m.-11:30 a.m. CT
Location: Hall A
Poster Session: Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract #7067 / Poster Board #59

About Pacritinib

Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. In August 2014, pacritinib was granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis including, but not limited to, patients with disease-related thrombocytopenia (low platelet counts); patients experiencing treatment-emergent thrombocytopenia on other JAK2 inhibitor therapy; or patients who are intolerant of, or whose symptoms are not well controlled (sub-optimally managed) on other JAK2 therapy. Clinical studies for pacritinib are currently subject to a full clinical hold issued by the U.S. Food and Drug Administration in February 2016.

CTI BioPharma and Baxalta Incorporated are parties to a worldwide license agreement to develop and commercialize pacritinib. CTI BioPharma and Baxalta will jointly commercialize pacritinib in the U.S. while Baxalta has exclusive commercialization rights for all indications outside the U.S.